...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Upcoming Zenith Events

Keystone Symposium: Epigenetics and Human Disease (X5); March 17-21, 2019 in Banff, Alberta, Canada. Sarah Attwell will be presenting a short talk titled "The BET Inhibitor ZEN-3694 Blocks Multiple Tumor Immune Suppressive Factors and has the Potential to Increase the Efficacy of Anti-PD1 Treatment"

BIO-Europe, March 25-27, 2019 in Vienna, Austria. 

AACR 2019, March 29 to April 3, 2019 in Atlanta, Georgia. Not on schedule right now with a regular abstract. However, Clinical Trial and Late-Breaking Abstract Titles Posted to Online Itinerary Planner at 4:30 p.m. ET on February 27th. Potential for some of the Phase 1 mCRPC trial data for either ZEN-3694 alone or in combo w/ enzalutamide to be presented.  

 

Share
New Message
Please login to post a reply